Novo Nordisk Sheds $30 Billion as Heart Drug Trial Fails, Derailing Diversification Hopes

Ziltivekimab Trial Collapse Erases $30 Billion in Value

Shares of Novo Nordisk plunged 9.3% to around $46.70 on Friday, lopping more than $30 billion off the company’s market capitalization and representing the stock’s worst intraday drop since February. The sell-off came after the drugmaker revealed that its experimental cardiovascular drug ziltivekimab had failed its late-stage clinical trial—dashing hopes of a lucrative new revenue stream beyond the wildly successful GLP-1 franchise led by Ozempic and Wegovy.

The phase 3 trial was designed to test whether ziltivekimab could reduce major adverse cardiovascular events such as heart attack or stroke. Novo Nordisk said the drug “did not meet” the study’s objectives and did not disclose by how much it may have lowered risk. Jefferies analysts noted that a risk reduction of at least 20% would have been necessary to consider the trial a success, calling the outcome “strategically negative” because it effectively erased a growth opportunity analysts believed could have exceeded $10 billion in annual sales.

The setback is especially painful because Novo Nordisk has been actively searching for ways to broaden its portfolio. The company had banked on building a cardiovascular care franchise, a need underscored by its market value already being down nearly 69% from an all-time high of $635.7 billion in June 2024. With Friday’s drop, the market cap fell from $229.2 billion to $198.5 billion.

Even as the company pushes forward with oral formulations of Wegovy—launching tablets in the UAE and UK with plans for a global rollout—and fights a public legal battle with rival Eli Lilly over allegedly misleading advertising, the clinical miss raises fresh doubts about the next leg of growth.

What the Failure Means for Novo Nordisk’s Strategy

A Pipeline Gap That Now Looks Wider

Novo Nordisk’s immense reliance on its GLP-1 drugs has long been a double-edged sword. Ozempic and Wegovy have delivered stellar sales and a historic market capitalization rise, but they have also left the company dangerously dependent on one class of therapies. The failure of ziltivekimab removes the nearest, most tangible candidate to build a parallel cardiovascular franchise—something analysts at Goldman Sachs had highlighted as a critical plank for easing that concentration risk. Without it, the company must lean even harder on the tablet version of Wegovy and on other earlier-stage assets, none of which carry the same near-term blockbuster expectations.

Competitive Pressure from Lilly Intensifies

The timing is doubly uncomfortable because Novo Nordisk is locked in a bitter advertising spat with Eli Lilly. Earlier this month, the Danish firm accused Lilly of running ads that misled consumers by using outdated data to make Novo Nordisk’s products appear less effective. With Lilly’s own tirzepatide (Mounjaro/Zepbound) gaining ground in the obesity and type 2 diabetes markets, any perception that Novo Nordisk’s innovation engine is stalling could shift prescriber and payer sentiment. The trial result does not directly affect the potency or safety of Ozempic or Wegovy, but a weaker pipeline narrative hands rivals an easier story to tell.

Shareholder Confidence in the Post-GLP-1 Story Erodes

The market reaction itself is telling: even after the staggering decline from the 2024 peak, the company was still priced for a growth trajectory that assumed successful diversification. The ziltivekimab miss forces a reassessment of that premium. Long-term investors must now grapple with a lower probability that Novo Nordisk can replicate its GLP-1 windfall in another therapeutic area over the next five years. That has immediate implications for the stock’s valuation multiple, which had already been compressing.

Implications for Investors, Competitors, and the Pipeline

• Novo Nordisk’s immediate priority should be accelerating the global rollout of oral Wegovy and filing for US approval of the tablet, because that oral franchise is now the most visible near-term growth driver outside the injectable GLP-1 line.
• Investors should watch for any update on the company’s pipeline day or a planned R&D event; management may feel compelled to spotlight other cardiovascular or metabolic candidates earlier than anticipated to restore confidence.
• Competitors—especially Eli Lilly—can use the trial outcome to strengthen marketing claims about their own pipelines; Novo Nordisk’s public relations and legal teams will need to counter any narrative that the company’s innovation is stalling.
• Anyone tracking the broader GLP-1 space should note that a key patent cliff for semaglutide is still several years away; the diversification urgency is therefore not immediate cash-flow risk, but a strategic one that will play out over the medium term.